Lv1
44 积分 2025-03-31 加入
Correlation between messenger RNA expression and protein expression of immune checkpoint–associated molecules in bladder urothelial carcinoma: A retrospective study
14小时前
待确认
Anatomically distinct fibroblast subsets determine skin autoimmune patterns
7天前
已完结
AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancer
9天前
已完结
Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials
15天前
已完结
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
27天前
已完结
Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study
27天前
已完结
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
30天前
已完结
Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody–drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study
1个月前
已完结
Dual-payload ADCs move into first oncology clinical trials
2个月前
已完结
725 Phase I safety and preliminary efficacy of PM8002 in subjects with advanced solid tumors, a bispecific antibody targeting PD-L1 and VEGF-A
3个月前
已完结
皖公网安备34019202002308
